PL2148676T3 - Stosowanie sapacytabiny do leczenia choroby proliferacyjnej - Google Patents

Stosowanie sapacytabiny do leczenia choroby proliferacyjnej

Info

Publication number
PL2148676T3
PL2148676T3 PL08737080.5T PL08737080T PL2148676T3 PL 2148676 T3 PL2148676 T3 PL 2148676T3 PL 08737080 T PL08737080 T PL 08737080T PL 2148676 T3 PL2148676 T3 PL 2148676T3
Authority
PL
Poland
Prior art keywords
sapacitabine
proliferative disease
treat proliferative
treat
disease
Prior art date
Application number
PL08737080.5T
Other languages
English (en)
Polish (pl)
Inventor
Judy Chiao
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0708021A external-priority patent/GB0708021D0/en
Priority claimed from GB0723723A external-priority patent/GB0723723D0/en
Application filed filed Critical
Publication of PL2148676T3 publication Critical patent/PL2148676T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PL08737080.5T 2007-04-25 2008-04-24 Stosowanie sapacytabiny do leczenia choroby proliferacyjnej PL2148676T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0708021A GB0708021D0 (en) 2007-04-25 2007-04-25 Use
GB0723723A GB0723723D0 (en) 2007-12-04 2007-12-04 Use

Publications (1)

Publication Number Publication Date
PL2148676T3 true PL2148676T3 (pl) 2016-12-30

Family

ID=39719125

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08737080.5T PL2148676T3 (pl) 2007-04-25 2008-04-24 Stosowanie sapacytabiny do leczenia choroby proliferacyjnej

Country Status (6)

Country Link
US (2) US8536188B2 (enExample)
EP (1) EP2148676B1 (enExample)
JP (2) JP5852309B2 (enExample)
ES (1) ES2587381T3 (enExample)
PL (1) PL2148676T3 (enExample)
WO (1) WO2008132443A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0625283D0 (en) * 2006-12-19 2007-01-24 Cyclacel Ltd Combination
US8536188B2 (en) 2007-04-25 2013-09-17 Cyclacel Limited Dosing regimens for treatment of proliferative disorders comprising administration of sapacitabine
CA2723944A1 (en) * 2008-05-15 2009-11-19 Jan Balzarini Anti-cancer combination therapy
EP3560501A1 (en) * 2011-04-14 2019-10-30 Cyclacel Limited Dosage regimen for sapacitabine and decitabine in combination for treating acute myeloid leukemia
EP2874631A1 (en) * 2012-05-15 2015-05-27 Cyclacel Limited Dosage regimen for sapacitabine and seliciclib
US20150335637A1 (en) * 2013-01-07 2015-11-26 The Trustees Of The University Of Pennsylvania Compositions and methods for treating cutaneous t cell lymphoma
WO2021079129A1 (en) 2019-10-24 2021-04-29 Cyclacel Limited Dosing regimen
CN113727719A (zh) 2020-07-17 2021-11-30 德尔塔菲制药股份有限公司 血癌的新型治疗方法及新型治疗剂

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003223958B2 (en) * 2002-03-08 2007-04-19 Novartis Ag Combinations comprising epothilone derivatives and alkylating agents
US20050014716A1 (en) * 2003-05-21 2005-01-20 Wang Jin Wei Pancreatic cancer treatment
MX2007007611A (es) * 2004-12-21 2007-09-04 Schering Corp Nuevos inhibidores de la farnesil protein-transferasa como agentes antitumorales.
SI1849470T2 (sl) * 2005-01-26 2024-05-31 Taiho Pharmaceutical Co., Ltd. Zdravilo proti raku, ki vsebuje alfa,alfa,alfa-trifluorotimidin in zaviralec timidin-fosforilaze
WO2007022408A2 (en) * 2005-08-18 2007-02-22 Merck & Co., Inc. Combination methods of saha and targretin for treating cancer
GB0526419D0 (en) * 2005-12-23 2006-02-08 Cyclacel Ltd Formulation
GB0609530D0 (en) 2006-05-12 2006-06-21 Cyclacel Ltd Combination
GB0625283D0 (en) 2006-12-19 2007-01-24 Cyclacel Ltd Combination
US8536188B2 (en) 2007-04-25 2013-09-17 Cyclacel Limited Dosing regimens for treatment of proliferative disorders comprising administration of sapacitabine

Also Published As

Publication number Publication date
US20100125084A1 (en) 2010-05-20
JP5892565B2 (ja) 2016-03-23
ES2587381T3 (es) 2016-10-24
US8536188B2 (en) 2013-09-17
WO2008132443A1 (en) 2008-11-06
EP2148676A1 (en) 2010-02-03
US9675631B2 (en) 2017-06-13
JP5852309B2 (ja) 2016-02-03
JP2015013877A (ja) 2015-01-22
EP2148676B1 (en) 2016-05-25
JP2010525042A (ja) 2010-07-22
US20140142058A1 (en) 2014-05-22

Similar Documents

Publication Publication Date Title
BRPI0914614A2 (pt) 2-arilaminoquinazolinas para tratar doenças proliferativas
IL211985A0 (en) Unsymmetrical pyrrolobenzodiazepine-dimers for treatment of proliferative diseases
IL209855A0 (en) Supression of neuroedocrine diseases
BRPI0908026A2 (pt) Métodos para o tratamento de doenças do intestino
ZA201101818B (en) Modified release emulsions for application to skin or viginal mucosa
IL219974A0 (en) Therapeutic compounds and related methods of use
IL230335A (en) A drug used to treat cartilage disease
PL2205245T3 (pl) Zastosowanie terapeutyczne diaminofenotiazyn
GB0803018D0 (en) Therapeutic compounds and their use
GB0804685D0 (en) Therapeutic compounds and their use
GB0908193D0 (en) Treatment of disease state
GB0817208D0 (en) Therapeutic apsap compounds and their use
GB0807609D0 (en) Therapeutic compounds and their use
PL2148676T3 (pl) Stosowanie sapacytabiny do leczenia choroby proliferacyjnej
EP2300608A4 (en) METHODS OF TREATING SOLID TUMORS
IL211076A0 (en) Novel methylenedioxy phenolic compounds and their use to treat disease
ZA201003867B (en) Treatment of heart disease using b-blockers
GB0812913D0 (en) Therapeutic compounds and their use
ZA201005783B (en) Hard to reach fracture applicator strap
GB0723100D0 (en) Treatment of HFnEF
GB0802128D0 (en) Therapeutic compounds and their use
GB0821539D0 (en) Therapeutic compounds and their use
GB0815134D0 (en) Therapeutic compounds and their use
GB0817859D0 (en) Treatment of proteostatic disease
GB0819543D0 (en) Treatment of proteostatic disease